165 related articles for article (PubMed ID: 31124579)
1. Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.
Rezk T; Lachmann HJ; Fontana M; Naharro AM; Sachchithanantham S; Mahmood S; Petrie A; Whelan CJ; Pinney JH; Foard D; Lane T; Youngstein T; Wechalekar AD; Hawkins PN; Gillmore JD
Br J Haematol; 2019 Aug; 186(3):460-470. PubMed ID: 31124579
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow-up.
Basset M; Kimmich CR; Schreck N; Krzykalla J; Dittrich T; Veelken K; Goldschmidt H; Seckinger A; Hose D; Jauch A; Müller-Tidow C; Benner A; Hegenbart U; Schönland SO
Br J Haematol; 2021 Oct; 195(2):230-243. PubMed ID: 34341985
[TBL] [Abstract][Full Text] [Related]
3. Clinical Value of Natriuretic Peptides in Predicting Time to Dialysis in Stage 4 and 5 Chronic Kidney Disease Patients.
Sundqvist S; Larson T; Cauliez B; Bauer F; Dumont A; Le Roy F; Hanoy M; Fréguin-Bouilland C; Godin M; Guerrot D
PLoS One; 2016; 11(8):e0159914. PubMed ID: 27548064
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System.
Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR
JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764
[TBL] [Abstract][Full Text] [Related]
5. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.
Kastritis E; Papassotiriou I; Merlini G; Milani P; Terpos E; Basset M; Akalestos A; Russo F; Psimenou E; Apostolakou F; Roussou M; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Fotiou D; Ziogas DC; Papadopoulou E; Pamboucas C; Dimopoulos MA; Palladini G
Blood; 2018 Apr; 131(14):1568-1575. PubMed ID: 29386197
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
[No Abstract] [Full Text] [Related]
7. Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study.
Zaroui A; Kharoubi M; Gounot R; Oghina S; Degoutte C; Bezard M; Galat A; Guendouz S; Roulin L; Audard V; Leroy V; Teiger E; Poullot E; Molinier-Frenkel V; Le Bras F; Belhadj K; Bastard JP; Fellahi S; Shourick J; Lemonier F; Damy T
ESC Heart Fail; 2024 Jun; 11(3):1707-1719. PubMed ID: 38444090
[TBL] [Abstract][Full Text] [Related]
8. A risk stratification for systemic immunoglobulin light-chain amyloidosis with renal involvement.
Li T; Huang X; Wang Q; Zhao L; Ren G; Chen W; Zheng C; Zhou M; Jiang Q; Yin R; Liu Z
Br J Haematol; 2019 Nov; 187(4):459-469. PubMed ID: 31348519
[TBL] [Abstract][Full Text] [Related]
9. Relation of Kidney Function Decline and NT-proBNP With Risk of Mortality and Readmission in Acute Decompensated Heart Failure.
McCallum W; Tighiouart H; Kiernan MS; Huggins GS; Sarnak MJ
Am J Med; 2020 Jan; 133(1):115-122.e2. PubMed ID: 31247182
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of cardiac biomarkers for death in a non-dialysis chronic kidney disease population.
Vickery S; Webb MC; Price CP; John RI; Abbas NA; Lamb EJ
Nephrol Dial Transplant; 2008 Nov; 23(11):3546-53. PubMed ID: 18562472
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study.
Nicol M; Vergaro G; Damy T; Kharoubi M; Baudet M; Canuti ES; Aimo A; Castiglione V; Emdin M; Royer B; Harel S; Cohen-Solal A; Arnulf B; Logeart D
Front Cardiovasc Med; 2023; 10():1179968. PubMed ID: 37600055
[TBL] [Abstract][Full Text] [Related]
13. Cardiorenal status using amino-terminal pro-brain natriuretic peptide and cystatin C on cardiac resynchronization therapy outcomes: From the BIOCRT Study.
Truong QA; Szymonifka J; Januzzi JL; Contractor JH; Deaño RC; Chatterjee NA; Singh JP
Heart Rhythm; 2019 Jun; 16(6):928-935. PubMed ID: 30590191
[TBL] [Abstract][Full Text] [Related]
14. Biohumoral markers as predictor of right ventricular dysfunction in AL Amyloidosis.
Cappelli F; Baldasseroni S; Bergesio F; Padeletti L; Attanà P; Pignone AM; Grifoni E; Ciuti G; Fabbri A; Tarantini F; Marchionni N; Gensini GF; Perfetto F
Amyloid; 2014 Jun; 21(2):97-102. PubMed ID: 24517408
[TBL] [Abstract][Full Text] [Related]
15. Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction?
van Kimmenade RR; Januzzi JL; Baggish AL; Lainchbury JG; Bayes-Genis A; Richards AM; Pinto YM
J Am Coll Cardiol; 2006 Oct; 48(8):1621-7. PubMed ID: 17045898
[TBL] [Abstract][Full Text] [Related]
16. Procalcitonin and N-Terminal Pro-B-Type Natriuretic Peptide for Prognosis in Septic Acute Kidney Injury Patients Receiving Renal Replacement Therapy.
Sheng X; Yang J; Yu G; Fei Y; Bao H; Yin J; Huang W; Tian Z; Wang N; Ronco C
Blood Purif; 2019; 48(3):262-271. PubMed ID: 31311006
[TBL] [Abstract][Full Text] [Related]
17. Increase in N-terminal pro-brain natriuretic peptide levels, renal function and cardiac disease in the oldest old.
Poortvliet R; de Craen A; Gussekloo J; de Ruijter W
Age Ageing; 2015 Sep; 44(5):841-7. PubMed ID: 26209786
[TBL] [Abstract][Full Text] [Related]
18. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis.
Palladini G; Barassi A; Klersy C; Pacciolla R; Milani P; Sarais G; Perlini S; Albertini R; Russo P; Foli A; Bragotti LZ; Obici L; Moratti R; Melzi d'Eril GV; Merlini G
Blood; 2010 Nov; 116(18):3426-30. PubMed ID: 20644111
[TBL] [Abstract][Full Text] [Related]
19. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure.
Palladini G; Foli A; Milani P; Russo P; Albertini R; Lavatelli F; Obici L; Perlini S; Moratti R; Merlini G
Am J Hematol; 2012 May; 87(5):465-71. PubMed ID: 22389105
[TBL] [Abstract][Full Text] [Related]
20. Competing Risk of Cardiac Status and Renal Function During Hospitalization for Acute Decompensated Heart Failure.
Salah K; Kok WE; Eurlings LW; Bettencourt P; Pimenta JM; Metra M; Verdiani V; Tijssen JG; Pinto YM
JACC Heart Fail; 2015 Oct; 3(10):751-61. PubMed ID: 26449995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
